Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
- Previous Close
59.53 - Open
59.00 - Bid 57.64 x --
- Ask 57.87 x --
- Day's Range
56.69 - 59.88 - 52 Week Range
43.41 - 64.25 - Volume
823,828 - Avg. Volume
462,028 - Market Cap (intraday)
6.922B - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
28.39 - EPS (TTM)
2.03 - Earnings Date --
- Forward Dividend & Yield 0.56 (0.97%)
- Ex-Dividend Date May 23, 2023
- 1y Target Est
61.62
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry, and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.
www.eastonpharma.cnRelated News
Performance Overview: 688513.SS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688513.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688513.SS
Valuation Measures
Market Cap
6.92B
Enterprise Value
5.64B
Trailing P/E
28.68
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.98
Price/Book (mrq)
2.64
Enterprise Value/Revenue
4.88
Enterprise Value/EBITDA
21.92
Financial Highlights
Profitability and Income Statement
Profit Margin
20.26%
Return on Assets (ttm)
--
Return on Equity (ttm)
9.02%
Revenue (ttm)
1.12B
Net Income Avi to Common (ttm)
226.29M
Diluted EPS (ttm)
2.03
Balance Sheet and Cash Flow
Total Cash (mrq)
1.42B
Total Debt/Equity (mrq)
6.81%
Levered Free Cash Flow (ttm)
--
Research Analysis: 688513.SS
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 688513.SS
688513.SS does not have Company Insights